HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget, 5(16), 7138–7148.
https://doi.org/10.18632/oncotarget.2231Since its creation, Institut Roche has translated its expertise into numerous successful scientific publications
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget, 5(16), 7138–7148.
https://doi.org/10.18632/oncotarget.2231
A cancer model for the angiogenic switch. Journal of theoretical biology, 360, 21–33.
https://doi.org/10.1016/j.jtbi.2014.06.020
Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes. Immunology letters, 161(1), 133–137.
https://doi.org/10.1016/j.imlet.2014.05.011
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 28(12), 2367–2375.
https://doi.org/10.1038/leu.2014.137
Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC cancer, 14, 178.
https://doi.org/10.1186/1471-2407-14-178
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecologic oncology, 132(1), 181–187.
https://doi.org/10.1016/j.ygyno.2013.10.013
Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma. The American journal of pathology, 184(1), 282–295.
https://doi.org/10.1016/j.ajpath.2013.09.018
Mitochondrial oxidative stress is the Achille’s heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget, 4(11), 1986–1998.
https://doi.org/10.18632/oncotarget.1420
Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics. Pharm Res 30, 2355–2367 (2013).
https://doi.org/10.1007/s11095-013-1079-3Results :99/110